Home › Funds › Kynam Capital Management, LP › TVTX

Kynam Capital Management, LP position in TVTX

TRAVERE THERAPEUTICS INC · Health Care

Kynam Capital Management, LP reported holding 2,000,000 shares of TVTX (TRAVERE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$113.6M, representing 6.28% of its reported portfolio and ranking #7 among its reported holdings. Kynam Capital Management, LP has disclosed TVTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)2.00M sh
Reported value held$113.62M
Portfolio Weight6.28%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Kynam Capital Management, LP's TVTX position evolved

Kynam Capital Management, LP first disclosed a stake in TVTX in Q3 2023 at 15,100 shares (US$135K). The position peaked in Q2 2026 at 2,000,000 shares, worth US$113.6M. Across 12 filings, Kynam Capital Management, LP increased the stake 4 time(s), trimmed it 5 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 2,000,000 shares valued at US$113.6M — an increase of 1,945,100 shares quarter over quarter.. Notable position changes include a 13145% increase in Q4 2023 (shares fell 14% over the following quarter), a 89% trim in Q1 2026 (shares rose 91% over the following quarter), a 3543% increase in Q2 2026 (shares rose 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 15.10K $134.99K New
Q4 2023 2.00M $17.98M Add
Q1 2024 2.00M $15.42M Hold
Q2 2024 2.02M $16.62M Add
Q3 2024 1.37M $19.19M Reduce
Q4 2024 1.80M $31.40M Add
Q1 2025 1.80M $32.31M Hold
Q2 2025 1.54M $22.80M Reduce
Q3 2025 949.73K $22.70M Reduce
Q4 2025 517.88K $19.79M Reduce
Q1 2026 54.90K $1.63M Reduce
Q2 2026 2.00M $113.62M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TVTX and 13F data

TVTX (TRAVERE THERAPEUTICS INC) is a Health Care company. 56 other funds we track also report a position in TVTX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$213.2M), Rock Springs Capital Management LP (US$123.8M), Stephens Investment Management Group LLC (US$106.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TVTX

All TVTX fund holders →

FAQ

How long has Kynam Capital Management, LP held TVTX?

Kynam Capital Management, LP has disclosed TVTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Kynam Capital Management, LP's current position in TVTX?

As of Q2 2026, Kynam Capital Management, LP holds 2.00M shares of TVTX (TRAVERE THERAPEUTICS INC), valued at $113.62M, representing 6.28% of its reported portfolio and ranking #7.

Has Kynam Capital Management, LP been buying or selling TVTX?

In the latest 13F filing (Q2 2026), Kynam Capital Management, LP increased its position in TVTX. The position peaked in Q2 2026 at 2.00M shares.

Which other funds hold TVTX?

Other major institutional holders of TVTX include PERCEPTIVE ADVISORS LLC, Rock Springs Capital Management LP, Stephens Investment Management Group LLC, among 56 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.